Margaret H. Collins, MD
- Staff Pathologist, Division of Pathology
- Director, GI Pathology
- Professor, UC Department of Pathology and Laboratory Medicine
- UC Department of Pediatrics
- margaret.collins@cchmc.org
- Board Certified
About
Biography
I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.
My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.
I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.
Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.
BS: Fordham University, NY, 1972.
MD: Georgetown University, Washington, D.C., 1977.
Residency: Pathology, New York Hospital, NY, 1977-80; Pathology, Columbia-Presbyterian Medical Center, NY, 1980-83.
Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, N.Y., 1983-85; Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87.
Certification: Pathology, 1981; Pediatric Pathology, 1991.
Interests
Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders
Services and Specialties
Colorectal Disorders, Pathology, Eosinophilic Disorders
Research Areas
Pathology, Eosinophilic Disorders
Publications
Induction of sustained remission and reversal of pathologic transcriptome achieved with tezepelumab in an adolescent with eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:3147-3149.e2.
TH2 cell compensatory effect following benralizumab treatment for eosinophilic gastritis. Journal of Allergy and Clinical Immunology. 2024; 154:1325-1332.e2.
Long-term durability between parent and child patient-reported outcomes in eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2024; 154:1232-1240.e12.
Two Clinical Trials Assessing Treatments for Eosinophilic Esophagitis. Reply. The New England Journal of Medicine. 2024; 391:1067-1068.
Losartan Treatment Reduces Esophageal Eosinophilic Inflammation in a Subset of Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2427-2438.e3.
Challenging assumptions about the demographics of eosinophilic gastrointestinal diseases: A systematic review. 2024; 3:100260.
Clinical and molecular correlates of the Index of Severity for Eosinophilic Esophagitis. Journal of Allergy and Clinical Immunology. 2024; 154:375-386.e4.
Transnasal Endoscopy Acquires Esophageal Biopsies Adequate for Comprehensive Pathology Evaluation in Patients With Eosinophilic Esophagitis. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2024; 27:327-334.
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. The New England Journal of Medicine. 2024; 390:2239-2251.
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis. The New England Journal of Medicine. 2024; 390:2252-2263.
From the Blog
Tale of Two Studies Shows Mixed Progress Against EoE
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD6/26/2024
Artificial Intelligence Holds the Key to Diagnosing Rare Esophageal Food Allergy Disease
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD10/25/2021
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey